يعرض 4,281 - 4,300 نتائج من 4,694 نتيجة بحث عن '(( significant decrease decrease ) OR ( significance test decrease ))~', وقت الاستعلام: 0.37s تنقيح النتائج
  1. 4281

    Table 3_Breeding indoor watercress for enhanced crop biofortification: harnessing natural variation of wild germplasm.docx حسب Yufei Qian (21575504)

    منشور في 2025
    "…Two glucosinolate compounds responded differently to blue light, as indolyl-3-methyl-glucosinolate increased while 4-phenylbutyl-glucosinolate decreased, but the other glucosinolate compounds tested, namely, 6-methyl-sulfinyloctyl-glucosinolate, 7-methyl-sulfinyloctyl-glucosinolate, 8-methyl-sulfinyloctyl-glucosinolate, and 2-phenylethyl-glucosinolate, showed varying responses to blue light depending on genotype. …"
  2. 4282

    Neurochemical identity of dFB<sup>23E10</sup>Ո<sup>84C10</sup> neurons. حسب Joseph D. Jones (13883524)

    منشور في 2025
    "…A Kruskal–Wallis ANOVA followed by Dunn’s multiple comparisons revealed that acutely silencing VGlut-AD; 84C10-DBD and 84C10-AD; ChAT-DBD neurons significantly decreases sleep. ****<i>P</i> < 0.0001. …"
  3. 4283

    Graphical Abstract. حسب Furkan Özdemir (21560297)

    منشور في 2025
    "…Peak VO<sub>2</sub> (p < 0.001), MET (p < 0.001), oxygen pulse (p = 0.006), knee extensor (p < 0.001) and handgrip strength decreased significantly within CG (p = 0.009). MET (p < 0.001) and %handgrip strength increased significantly in ACG compared to AG and CG (p = 0.021). …"
  4. 4284

    PONE-Dataset. حسب Furkan Özdemir (21560297)

    منشور في 2025
    "…Peak VO<sub>2</sub> (p < 0.001), MET (p < 0.001), oxygen pulse (p = 0.006), knee extensor (p < 0.001) and handgrip strength decreased significantly within CG (p = 0.009). MET (p < 0.001) and %handgrip strength increased significantly in ACG compared to AG and CG (p = 0.021). …"
  5. 4285

    Demographic characteristics of groups. حسب Furkan Özdemir (21560297)

    منشور في 2025
    "…Peak VO<sub>2</sub> (p < 0.001), MET (p < 0.001), oxygen pulse (p = 0.006), knee extensor (p < 0.001) and handgrip strength decreased significantly within CG (p = 0.009). MET (p < 0.001) and %handgrip strength increased significantly in ACG compared to AG and CG (p = 0.021). …"
  6. 4286

    Table 1_Schistosomiasis in Ghana from baseline to now: the impact of fifteen years of interventions.docx حسب Joseph Opare (5437238)

    منشور في 2025
    "…Background<p>Schistosomiasis is a major public health problem in Ghana, significantly impacted by the construction of dams during the 1960s that resulted in the creation of Lake Volta. …"
  7. 4287

    Data Sheet 1_Impact of a structured food sequence and mobile health monitoring on gestational diabetes outcomes: a clinical trial.pdf حسب Ria Murugesan (21795620)

    منشور في 2025
    "…A p-value <0.05 was considered statistically significant.</p>Results<p>The intervention group showed significant reductions in 1-h and 2-h postprandial blood glucose levels (−8.41 mg/dL and −7.56 mg/dL respectively, both p < 0.001), decreased LDL cholesterol (−7.33 mg/dL, p < 0.001), increased HDL cholesterol (+6.15 mg/dL, p < 0.001), and improved hemoglobin levels. …"
  8. 4288

    White-to-opaque switching frequencies of double TF heterozygotes in a <i>WOR1</i>(KR-to-G) strain background. حسب Collin Ganser (8924843)

    منشور في 2025
    "…Double heterozygote strains that exhibited switching frequencies that were significantly higher than their expected switching frequencies (positive interactions) are shown in red and those significantly lower (negative interactions) are shown in blue (based on multiplying the switching frequencies of the corresponding single heterozygotes).…"
  9. 4289

    Data Sheet 1_Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and... حسب Zachary D. Wallen (19986522)

    منشور في 2024
    "…Known associations between genomic alterations and immunotherapy markers were observed including significantly lower TMB levels in tumors with therapy-associated alterations and significantly higher PD-L1 levels in tumors with ALK, MET, BRAF, or ROS1 driver mutations. …"
  10. 4290

    Table 4_Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel... حسب Zachary D. Wallen (19986522)

    منشور في 2024
    "…Known associations between genomic alterations and immunotherapy markers were observed including significantly lower TMB levels in tumors with therapy-associated alterations and significantly higher PD-L1 levels in tumors with ALK, MET, BRAF, or ROS1 driver mutations. …"
  11. 4291

    Table 1_Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel... حسب Zachary D. Wallen (19986522)

    منشور في 2024
    "…Known associations between genomic alterations and immunotherapy markers were observed including significantly lower TMB levels in tumors with therapy-associated alterations and significantly higher PD-L1 levels in tumors with ALK, MET, BRAF, or ROS1 driver mutations. …"
  12. 4292

    Table 1_Ten-year outcomes of repeat keratoplasty for optical indications.docx حسب Victoria Grace Dimacali (20597690)

    منشور في 2025
    "…Cox multiple regression analysis showed male gender (p = 0.023), PK regraft (p = 0.003), regraft rejection (p = 0.003), and initial graft indications of pseudophakic bullous keratopathy (p = 0.005) and aphakic bullous keratopathy (p = 0.004) to be risk factors for regraft failure, while longer time to regraft was associated with decreased risk of failure (p = 0.013).</p>Conclusion<p>Performing EK for failed optical PK or EK significantly improved regraft survival compared to repeat PK. …"
  13. 4293

    Table 5_Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel... حسب Zachary D. Wallen (19986522)

    منشور في 2024
    "…Known associations between genomic alterations and immunotherapy markers were observed including significantly lower TMB levels in tumors with therapy-associated alterations and significantly higher PD-L1 levels in tumors with ALK, MET, BRAF, or ROS1 driver mutations. …"
  14. 4294

    Image 1_Ten-year outcomes of repeat keratoplasty for optical indications.png حسب Victoria Grace Dimacali (20597690)

    منشور في 2025
    "…Cox multiple regression analysis showed male gender (p = 0.023), PK regraft (p = 0.003), regraft rejection (p = 0.003), and initial graft indications of pseudophakic bullous keratopathy (p = 0.005) and aphakic bullous keratopathy (p = 0.004) to be risk factors for regraft failure, while longer time to regraft was associated with decreased risk of failure (p = 0.013).</p>Conclusion<p>Performing EK for failed optical PK or EK significantly improved regraft survival compared to repeat PK. …"
  15. 4295

    Table 2_Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel... حسب Zachary D. Wallen (19986522)

    منشور في 2024
    "…Known associations between genomic alterations and immunotherapy markers were observed including significantly lower TMB levels in tumors with therapy-associated alterations and significantly higher PD-L1 levels in tumors with ALK, MET, BRAF, or ROS1 driver mutations. …"
  16. 4296

    Table 5_Ten-year outcomes of repeat keratoplasty for optical indications.docx حسب Victoria Grace Dimacali (20597690)

    منشور في 2025
    "…Cox multiple regression analysis showed male gender (p = 0.023), PK regraft (p = 0.003), regraft rejection (p = 0.003), and initial graft indications of pseudophakic bullous keratopathy (p = 0.005) and aphakic bullous keratopathy (p = 0.004) to be risk factors for regraft failure, while longer time to regraft was associated with decreased risk of failure (p = 0.013).</p>Conclusion<p>Performing EK for failed optical PK or EK significantly improved regraft survival compared to repeat PK. …"
  17. 4297

    Table 2_Ten-year outcomes of repeat keratoplasty for optical indications.docx حسب Victoria Grace Dimacali (20597690)

    منشور في 2025
    "…Cox multiple regression analysis showed male gender (p = 0.023), PK regraft (p = 0.003), regraft rejection (p = 0.003), and initial graft indications of pseudophakic bullous keratopathy (p = 0.005) and aphakic bullous keratopathy (p = 0.004) to be risk factors for regraft failure, while longer time to regraft was associated with decreased risk of failure (p = 0.013).</p>Conclusion<p>Performing EK for failed optical PK or EK significantly improved regraft survival compared to repeat PK. …"
  18. 4298

    Table 3_Ten-year outcomes of repeat keratoplasty for optical indications.docx حسب Victoria Grace Dimacali (20597690)

    منشور في 2025
    "…Cox multiple regression analysis showed male gender (p = 0.023), PK regraft (p = 0.003), regraft rejection (p = 0.003), and initial graft indications of pseudophakic bullous keratopathy (p = 0.005) and aphakic bullous keratopathy (p = 0.004) to be risk factors for regraft failure, while longer time to regraft was associated with decreased risk of failure (p = 0.013).</p>Conclusion<p>Performing EK for failed optical PK or EK significantly improved regraft survival compared to repeat PK. …"
  19. 4299

    Table 4_Ten-year outcomes of repeat keratoplasty for optical indications.docx حسب Victoria Grace Dimacali (20597690)

    منشور في 2025
    "…Cox multiple regression analysis showed male gender (p = 0.023), PK regraft (p = 0.003), regraft rejection (p = 0.003), and initial graft indications of pseudophakic bullous keratopathy (p = 0.005) and aphakic bullous keratopathy (p = 0.004) to be risk factors for regraft failure, while longer time to regraft was associated with decreased risk of failure (p = 0.013).</p>Conclusion<p>Performing EK for failed optical PK or EK significantly improved regraft survival compared to repeat PK. …"
  20. 4300

    Table 3_Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel... حسب Zachary D. Wallen (19986522)

    منشور في 2024
    "…Known associations between genomic alterations and immunotherapy markers were observed including significantly lower TMB levels in tumors with therapy-associated alterations and significantly higher PD-L1 levels in tumors with ALK, MET, BRAF, or ROS1 driver mutations. …"